Product Description
MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK) and zeta-chain-associated protein kinase 70 (ZAP70) that is being investigated as an RA treatment.Ê (Sourced from: https://acrabstracts.org/abstract/efficacy-and-safety-of-mk-8457-a-novel-syk-inhibitor-for-the-treatment-of-rheumatoid-arthritis-in-two-randomized-controlled-phase-2-studies/)
Mechanisms of Action: SYK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Phase 1: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A Phase IIa POC study to evaluate Safety, Tolerability and Efficacy in Subjects with RA | P2 |
Completed |
Arthritis, Rheumatoid |
2016-10-19 |
|
| Proof-of-Concept of MK-8457 in patients with Rheumatoid Arthritis | P2 |
Terminated |
Arthritis, Rheumatoid |
2014-10-10 |
|
| MK-8457-010 | P2 |
Terminated |
Arthritis, Rheumatoid |
2013-10-08 |
|
| P08683, MK-8457-008 | P2 |
Terminated |
Arthritis, Rheumatoid |
2013-10-03 |